Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419284PMC
http://dx.doi.org/10.2215/CJN.00760119DOI Listing

Publication Analysis

Top Keywords

cost immunosuppressive
4
immunosuppressive drugs
4
drugs patient
4
patient kidney
4
kidney transplant
4
cost
1
drugs
1
patient
1
kidney
1
transplant
1

Similar Publications

[Updates in General Management and Frequent Complications Following Adult Liver Transplant].

Rev Med Chil

June 2024

Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Liver transplantation (LT) is a cost-effective therapy for advanced liver disease. Although LT significantly improves long-term survival, it requires strict control of immunosuppressants and their potential complications. Several available immunosuppressive drugs include glucocorticoids, calcineurin inhibitors, mycophenolate, mTOR inhibitors, and anti-CD25 antibodies.

View Article and Find Full Text PDF

We compared the cost-effectiveness of gemcitabine plus nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX)-standard first-line treatments for metastatic pancreatic cancer in Japan. This retrospective cohort study included patients with metastatic pancreatic cancer treated at the National Cancer Center Hospital East in Japan between December 2013 and February 2017. A partitioned survival model, featuring five mutually exclusive health states, was developed.

View Article and Find Full Text PDF

Strongyloides stercoralis infection in a patient initiating corticosteroid therapy for hypereosinophilia: A case report.

Parasitol Int

December 2024

Department of Medical Microbiology, Faculty of Medicine, TOBB University of Economics and Technology, Ankara, Turkey; Department of Medical Microbiology, Faculty of Medicine, Cyprus International University, Nicosia, Cyprus.

Strongyloides stercoralis (S. stercoralis) is a soil-transmitted nematode that is endemic to tropical and subtropical regions. S.

View Article and Find Full Text PDF

The 2024 APLAR Consensus on the Management of Lupus Nephritis.

Int J Rheum Dis

January 2025

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

The APLAR has published a set of recommendations on the management of systemic lupus erythematosus (SLE) in 2021. The current consensus paper supplements and updates specifically the treatment of lupus nephritis (LN) according to two rounds of Delphi exercise from members of the APLAR SLE special interest group, invited nephrologists, histopathologists, and lupus nephritis patients. For initial treatment of LN, we recommend a combination of glucocorticoids (GCs) with cyclophosphamide (CYC), mycophenolate mofetil (MMF), or the calcineurin inhibitors (CNIs) as first-line options.

View Article and Find Full Text PDF
Article Synopsis
  • The study highlights the ongoing challenges faced by ulcerative colitis (UC) patients in Japan despite existing treatments, focusing on their health-related quality of life (HRQoL) and productivity losses.
  • About 83.6% of participants were on non-biologic treatments, with a significant portion reporting persistent symptoms and a notable percentage experiencing anxiety and depression, which negatively impacted their work productivity by an average of 29.3%.
  • The results emphasize the need for new interventions to improve treatment outcomes as many patients still experience high disease burden and indirect costs.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!